Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:01:34 2024-04-29 pm EDT			5-day change	1st Jan Change
25.64 ^USD	+0.94%		-2.36%	-10.94%

05:55am	Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	MT
Apr. 29	J&J, Bristol Myers lose challenges to US drug price negotiation program	RE

PFIZER INC : UBS reaffirms its Neutral rating

January 30, 2024 at 09:03 am EST

In a research note, UBS analyst Trung Huynh has maintained his recommendation on the stock with a Neutral rating. The target price remains set at USD 29.

Latest news about Pfizer, Inc.

Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	11:55pm	MT
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug	Apr. 29	DJ
Tesla Rally Boosts S&P 500, Nasdaq; This Week's Earnings, Fed Decision in Focus	Apr. 29	MT
Equity Markets Rise With Key Earnings, Fed Decision in Focus	Apr. 29	MT
US FDA grants full approval for Pfizer's cervical cancer drug	Apr. 29	RE
Equities Higher as Traders Await This Week's Key Earnings, Fed Decision	Apr. 29	MT
S&P 500 Companies' Latest Quarterly Results Mixed so Far, Oppenheimer Says	Apr. 29	MT
Equities Rise Intraday as Traders Await This Week's Key Earnings, Fed Decision	Apr. 29	MT
CAC40: limited downturn, despite the beginnings of a rate cut	Apr. 29	CF
CAC40: limited erosion, despite the beginnings of a rate cut	Apr. 29	CF
Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy	Apr. 29	MT
Pfizer: presents new data at ASCO 2024	Apr. 29	CF
Big tech saves the day, again	Apr. 29
CAC40: France's rating maintained = non-event	Apr. 29	CF
Earnings, Tech Outlooks Lift Wall Street Pre-Bell; Asia, Europe Up	Apr. 29	MT
CAC40: starts the week slightly up, crosses the 8100 mark	Apr. 29	CF
CAC 40: cautious rise ahead of a busy week	Apr. 29	CF
S&P 500 Posts First Weekly Gain Since March as Tech, Consumer Discretionary Lead Rise on Better-Than-Expected Earnings	Apr. 26	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 26	MT
Pfizer Gets FDA Approval for Bleeding Disorder Treatment	Apr. 26	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	Apr. 26	MT
Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment	Apr. 26	MT
Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment	Apr. 26	MT
Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment	Apr. 26	MT

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.64 USD

Average target price

31.62 USD

Spread / Average Target

+23.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-10.94%	145B
ELI LILLY AND COMPANY	+26.47%	664B
NOVO NORDISK A/S	+26.74%	567B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
ASTRAZENECA PLC	+13.43%	234B
NOVARTIS AG	+4.71%	199B
ROCHE HOLDING AG	-9.53%	196B
AMGEN INC.	-4.04%	148B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

PFIZER INC : UBS reaffirms its Neutral rating

Latest news about Pfizer, Inc.

Chart Pfizer, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Pfizer, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals